Breaking News
March 20, 2018 - Post-Transplant Fatty Liver Disease on the Rise
March 20, 2018 - New mutation linked to ovarian cancer can be passed down through dad
March 20, 2018 - Scotland study aims to offer precise diagnoses for people with rare genetic diseases
March 20, 2018 - Stem cell treatment may help rejuvenate ovaries, avoid effects of premature menopause
March 20, 2018 - FDA Approves Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid) for the Treatment of Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
March 20, 2018 - Death Strikes Young in RA
March 20, 2018 - Quiescent cells also mutate
March 20, 2018 - Stem cell-derived ocular cells treat severe AMD
March 20, 2018 - Mediterranean diet appears to be good for postmenopausal women’s bones and muscles
March 20, 2018 - Scientists discover rare childhood liver cancer’s ability to metastasize to the brain
March 20, 2018 - Treating metastatic breast cancer with immunotherapy
March 20, 2018 - The 5:2 diet could have beneficial impact on important risk markers for cardiovascular disease
March 20, 2018 - Congress tackles the opioid epidemic. But how much will it help?
March 20, 2018 - Neanderthals Just Part of the Evolutionary Puzzle
March 20, 2018 - Higher Mortality With Surgery for Early NSCLC
March 20, 2018 - Researchers go skin deep to explore what causes wrinkles
March 20, 2018 - E-cigarette use linked to fat accumulation in the liver
March 20, 2018 - Fearful worms provide new clues about human anxiety
March 20, 2018 - Oral micronized progesterone may reduce hot flashes, night sweats in perimenopausal women
March 20, 2018 - Newer treatment for type 2 diabetes reduces liver fat in patients with NAFLD
March 20, 2018 - I.D. Break: PrEP Map; Faulty Flu Meds; Better Zika Test?
March 20, 2018 - Bronchial thermoplasty can improve severe asthmatic cough
March 19, 2018 - Speeding up wound healing using nanofiber dressings
March 19, 2018 - Summit Announces New Analysis Showing Ezutromid Significantly Reduced Muscle Inflammation in Phase 2 Clinical Trial in DMD
March 19, 2018 - Optimizing Sham Acupuncture: That’s Improbable!
March 19, 2018 - Women who have gestational diabetes in pregnancy are at higher risk of future health issues
March 19, 2018 - Viagra cuts colorectal cancer risk in animal model
March 19, 2018 - Vitamin B12 supplementation could postpone disease progression in Parkinson’s patients
March 19, 2018 - Study shows that omega-6 fatty acids could protect against premature death
March 19, 2018 - TherapeuticsMD Announces FDA Acceptance of New Drug Application (NDA) and Prescription Drug User Fee Act (PDUFA) Date for TX-001HR
March 19, 2018 - Minorities More Sensitive To Pain? Pain Medicine News Report
March 19, 2018 - Low blood sugar poses unaddressed threat to people with type 2 diabetes
March 19, 2018 - ACEA goes live with exhaustive, searchable library of NovoCyte publications
March 19, 2018 - Consumption of low-calorie sweeteners could promote metabolic syndrome, increase diabetes risk
March 19, 2018 - Wearable medical patch shows promise for early detection of hypoglycemia in type 1 diabetes
March 19, 2018 - High-energy breakfast leads to better diabetes control and weight loss
March 19, 2018 - D.C. Week: Community Health Centers Get Azar’s Love
March 19, 2018 - Younger siblings of SIDS victims have four-fold increased risk of sudden death
March 19, 2018 - Toothpaste alone does not prevent dental erosion or hypersensitivity
March 19, 2018 - Discovery aids understanding of amyotrophic lateral sclerosis
March 19, 2018 - Hormone imbalance may be reason for higher diabetes rates among men with insufficient sleep
March 19, 2018 - Docs worry there’s ‘nowhere to send’ new and expectant moms with depression
March 19, 2018 - Obesity linked to increased DNA damage in breast epithelium of BRCA mutation carriers
March 19, 2018 - Heart rate increases with higher alcohol consumption
March 19, 2018 - Template produced for clinically validated DIY stethoscope
March 19, 2018 - Experts highlight nocturia as most common cause of poor night’s sleep
March 19, 2018 - Fit Middle-Aged Women May Fend Off Dementia Later
March 19, 2018 - Fake Insta Doc; Humana’s Weird Pay Bump Tax Trick; Few NPDB Searches
March 19, 2018 - Guidelines for fluoride intake—are they appropriate?
March 19, 2018 - Race and pre-pregnancy BMI may be key predictors of maternal weight gain
March 19, 2018 - Telediabetes program improves blood sugar control for veterans
March 19, 2018 - Research suggests breastfeeding as protective factor against obesity in high-birthweight infants
March 19, 2018 - Morning Break: House Nixes ‘Right-to-Try’ Bill; Purdue’s PR Makeover; Air in the Brain
March 19, 2018 - Heart researchers develop a new, promising imaging technique for cardiac arrhythmias
March 19, 2018 - Mice study shows how BPA exposure during pregnancy can lead to altered brain development
March 19, 2018 - Breastfeeding mothers who overeat may increase risk of health problems in offspring
March 19, 2018 - New mobile application can detect atrial fibrillation that causes strokes
March 19, 2018 - Study finds low rates of preconception counseling among women of childbearing age with diabetes
March 19, 2018 - Vitl Life Science Solutions announces launch of new Lu-mini at analytica 2018
March 19, 2018 - ObsEva SA Reports Positive Topline Results from IMPLANT2 Phase 3 Clinical Trial of Nolasiban in IVF
March 19, 2018 - D.C. Week: States Plead for Federal $$ in Opioid Fight
March 19, 2018 - Polycystic ovary syndrome – Genetics Home Reference
March 19, 2018 - Reducing co-payments improves patient, physician adherence to guideline-recommended treatment post-MI
March 19, 2018 - Normalizing estrogen levels can benefit female athletes with irregular menstrual periods
March 19, 2018 - Fitness trackers and virtual coaches motivate patients to exercise post cardiac rehab
March 19, 2018 - Atrial fibrillation patients could reduce risk of dementia by taking stroke prevention drugs
March 19, 2018 - Low sperm count more prevalent with other health problems finds study
March 19, 2018 - Male birth control pill taken once a day shows success
March 19, 2018 - AcelRx Announces Receipt of Type A FDA Meeting Minutes and Plans to Resubmit the DSUVIA New Drug Application in Q2 2018
March 19, 2018 - Eye Docs Adopt EHRs Despite Reservations
March 19, 2018 - CRISPR enhances cancer immunotherapy
March 19, 2018 - Study finds first evidence of delayed aging among Americans
March 19, 2018 - Aussies unaware of sun protection rules to prevent skin cancer
March 19, 2018 - Essential oils linked to abnormal breast development in boys
March 19, 2018 - ‘Tummy Tuck’ Relieved Postpartum Back Pain/Incontinence
March 19, 2018 - New biomarkers for neuroblastoma, a type of cancer in children
March 19, 2018 - Hookah Smoking Carries a Poisoning Risk
March 19, 2018 - Do Mood and Anxiety Affect MS Disability?
March 19, 2018 - Mean depth of ultrasonographic penetration greater in autism
March 19, 2018 - Platypus milk may help combat antibiotic resistance
A Role for Budesonide in Autoimmune Hepatitis?

A Role for Budesonide in Autoimmune Hepatitis?

image_pdfDownload PDFimage_print

Action Points

  • Note that this observational study of budesonide in autoimmune hepatitis suggests that the agent, which undergoes extensive first-pass metabolism, may be effective when more systemic steroids are not tolerated.
  • At baseline, the mean budesonide dose was 9 mg per day.

Budesonide may be an acceptable second-line treatment for autoimmune hepatitis among patients who experience steroid-induced side effects or who are dependent on high doses of prednisolone, a retrospective single-center analysis suggested.

Among 60 patients who were switched to budesonide from prednisolone, 55% were considered responders after 6 months of treatment, as were 70% after 12 months, according to Christoph Schramm, MD, and colleagues from University Medical Center Hamburg-Eppendorf in Germany.

In addition, the rates of biochemical response — defined as normalization of serum levels of aminotransferases and IgG — were 68% after 24 months and 70% after 36 months, the researchers reported in Clinical Gastroenterology and Hepatology.

Autoimmune hepatitis is characterized by liver inflammation, high levels of aminotransferases and IgG, and the presence of circulating autoantibodies such as antinuclear antibodies (ANA) and smooth muscle antibodies (SMA). Standard treatment involves corticosteroids alone or with azathioprine.

Prednisolone typically has been favored because of its efficacy in controlling liver inflammation, but an estimated 44% of patients develop steroid-associated side effects with this agent, and up to 15% are refractory and require alternative treatments.

Budesonide is a synthetic steroid derived from 16α-hydroxyprednisolone that has fewer adverse effects than prednisolone because its hepatic first-pass clearance exceeds 90%. This drug is not recommended for patients with cirrhosis because of adverse events associated with portosystemic shunting.

Previous studies evaluating budesonide in autoimmune hepatitis have had conflicting results, with one randomized trial showing efficacy for both remission and maintenance after 6 and 12 months but another showing low rates of response at 6 months. Moreover, longer-term data are sparse, and autoimmune hepatitis often requires lifelong therapy.

Therefore, to explore a possible role for budesonide among patients with inadequate responses or intolerance to prednisolone, Schramm and colleagues retrospectively analyzed data that had been collected prospectively at their center from 2001 to 2016.

Among 328 patients with autoimmune hepatitis in their database, 60 (51 women) had been switched to budesonide from prednisolone — 30 because of side effects and 30 because of the inability to taper the steroid dose sufficiently. The mean age at the time of diagnosis was 42, and most patients were positive for both ANA and SMA.

Concomitant autoimmune diseases were present in some patients, such as thyroid disease in 12%, diabetes in 7%, rheumatoid arthritis in 3%, and lupus in 2%.

The mean duration of prednisolone therapy before switching was 47 months, and the mean daily dose was 8.5 mg.

In 10 patients, budesonide was given as monotherapy, while 40 also received azathioprine, six were given mycophenolate mofetil (CellCept), and two received 6-mercaptopurine.

Mean alanine aminotransferase levels were 123 U/L at the beginning of budesonide treatment, declining to 45.7 U/L at 6 months (P<0.001) and thereafter remaining stable through 36 months, when the mean level was 50.3 U/L.

The mean serum IgG levels also declined, from 14.2 g/L at budesonide initiation to 12.2 g/L at 6 months (P=0.006), and were 12.8 g/L at 36 months.

The mean dose of budesonide was 9 mg/day at baseline, and the mean maintenance dosage was 6.2 mg/day.

Among patients who had switched to budesonide because of adverse effects with prednisolone, responses at 6, 12, 24, and 36 months were seen in 50%, 65%, 70%, and 72% of patients, respectively.

Among those who switched because of the inability to taper prednisolone, responses at those time points were seen in 60%, 75%, 64%, and 69%, respectively. The mean dosages were 5.8 mg after 6 months and 5.1 mg/day after 36 months, “showing efficacy of medium doses of budesonide in the group of patients with prior prednisolone dependency,” the authors noted.

A total of 17 patients switched back to prednisolone after a mean of 17.1 months, because of side effects or lack of efficacy. In nine of these, there was a flare of aminotransferase levels, three developed cirrhosis, and one had new onset bullous pemphigoid.

Among 15 patients who had osteopenia during prednisolone treatment, six had improved T-scores and eight remained stable during budesonide therapy, while only one had T-score worsening.

The lack of bone mineral density deterioration during budesonide treatment supports the use of this treatment approach among patients who did not respond to prednisolone, the authors suggested. “However, treatment efficacy and tolerance must be monitored because efficacy of budesonide may not suffice to maintain remission or control concomitant autoimmune disease and budesonide-induced side effects may occur in patients even in the absence of cirrhosis.”

In an accompanying editorial, Michael P. Manns, MD, of Hannover Medical School in Germany, and two colleagues said there is a need for additional treatments for autoimmune hepatitis that utilize different mechanisms of action, such as calcineurin inhibitors and monoclonal antibodies including rituximab (Rituxan) and infliximab (Remicade).

“It is hoped that ongoing initiatives will lead to a consensus approach for the development of effective second-line therapies for this difficult-to-treat group of patients,” the editorialists stated.

The limitations of the study, Schramm and colleagues wrote, included the retrospective design and the single tertiary care setting.

The study was supported by the YAEL Foundation, the German Research Foundation, and the Helmut and Hannelore Greve Foundation.

The Schramm and c0-authors reported financial relationships with the Falk Foundation and Falk Pharma.

The editorialists reported financial relationships with Novartis, Basel, the Falk Foundation, and the Falk Pharma.

  • Reviewed by
    F. Perry Wilson, MD, MSCE Assistant Professor, Section of Nephrology, Yale School of Medicine and Dorothy Caputo, MA, BSN, RN, Nurse Planner


last updated

Tagged with:

About author

Related Articles